Business Context and Reporting Period
This Form 8-K Current Report was filed by Madrigal Pharmaceuticals, Inc. on December 12, 2019, covering events occurring on December 10, 2019. The filing details the entry into a Material Definitive Agreement regarding a secondary offering of common stock.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a securities transaction.
- Transaction Type: Secondary offering (sale by existing stockholders).
- Shares Sold: 1,200,000 shares of common stock.
- Offering Price: $107.85 per share.
- Over-Allotment Option: 30-day option to purchase up to 180,000 additional shares.
- Company Proceeds: $0 (The Company will not receive any proceeds from this sale).
Material Changes
The material change reported is the execution of an Underwriting Agreement with Goldman Sachs & Co. LLC. Investment funds affiliated with Bay City Capital LLC (the "Selling Stockholders") are selling their shares. The closing of the sale is expected to occur on December 13, 2019, subject to customary conditions. This transaction represents a change in the company's shareholder base but does not alter the company's capital structure or cash position.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of operational risks. The primary contingency noted is the satisfaction of customary closing conditions for the transaction. The agreement includes standard indemnification obligations for the Company, Selling Stockholders, and Underwriters regarding liabilities under the Securities Act of 1933.
Investor Verification Checklist
- Verify the final closing date of the transaction (expected December 13, 2019).
- Confirm whether the 30-day over-allotment option for 180,000 shares was exercised.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific representations and warranties.
- Check subsequent filings for any dilution impact on existing shareholders due to the increased share count.